Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

Engineering >> 2019, Volume 5, Issue 1 doi: 10.1016/j.eng.2018.11.010

Engineered T Cell Therapies from a Drug Development Viewpoint

a Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
b Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA
c Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA 19104, USA
d Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
e Department of Immunology, Peking University, Beijing 100871, China

Received: 2018-07-03 Revised: 2018-10-19 Accepted: 2018-11-15 Available online: 2018-12-13

Next Previous

Abstract

Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life. Unlike chemical compounds and proteins, cells are living, self-replicating drugs that can be engineered to possess exquisite specificity. For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowing them with the capacity to recognize and kill tumor cells and form a memory pool that is ready to strike back against persisting malignant cells. Anti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinical efficacy for certain malignancies. The process of developing CART19 essentially follows the conventional “one gene, one drug, one disease” paradigm derived from Paul Ehrlich’s “magic bullet” concept. With major players within the pharmaceutical industry joining forces to commercialize this new category of “living drugs,” it is useful to use CART19 as an example to examine the similarities and differences in its development, compared with that of a conventional drug. In this way, we can assimilate existing knowledge and identify the most effective approach for advancing similar strategies. This article reviews the use of biomarker-based assays to guide the optimization of CAR constructs, preclinical studies, and the evaluation of clinical efficacy; adverse effects (AEs); and CART19 cellular kinetics. Advanced technologies and computational tools that enable the discovery of optimal targets, novel CAR binding domains, and biomarkers predicting clinical response and AEs are also discussed. We believe that the success of CART19 will lead to the development of other engineered T cell therapies in the same manner that the discovery of arsphenamine initiated the era of synthetic pharmaceuticals.

Figures

Fig. 1

Fig. 2

Fig. 3

Fig. 4

References

[ 1 ] Rappuoli R. Vaccines: science, health, longevity, and wealth. Proc Natl Acad Sci USA 2014;111(34):12282. link1

[ 2 ] Adedeji WA. The treasure called antibiotics. Ann Ib Postgrad Med 2016;14 (2):56–7. link1

[ 3 ] Riedel S. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005;18(1):21–5. link1

[ 4 ] National Center for Health Statistics. Health, United States, 2016: with chartbook on long-term trends in health. Report. Hyattsville: National Center for Health Statistics; 2017. link1

[ 5 ] Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016;66(4):271–89. link1

[ 6 ] Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010;116(20):4099–102. link1

[ 7 ] Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365 (8):725–33. link1

[ 8 ] Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3 (95):95ra73. link1

[ 9 ] Yousefi H, Yuan J, Keshavarz-Fathi M, Murphy JF, Rezaei N. Immunotherapy of cancers comes of age. Expert Rev Clin Immunol 2017;13(10):1001–15. link1

[10] Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 2015;14:642–62. Corrigenda in: Nat Rev Drug Discov 2016;15:143,660. link1

[11] Kumar M, Nagpal R, Hemalatha R, Verma V, Kumar A, Singh S, et al. Targeted cancer therapies: the future of cancer treatment. Acta Biomed 2012;83 (3):220–33. link1

[12] Brown C. Targeted therapy: an elusive cancer target. Nature 2016;537(7620): S106–8. link1

[13] Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA. Adoptive cell therapy—tumor-infiltrating lymphocytes, T-cell receptors, and chimeric antigen receptors. Semin Oncol 2015;42(4):626–39. link1

[14] Pettitt D, Arshad Z, Smith J, Stanic T, Hollander G, Brindley D. CAR-T cells: a systematic review and mixed methods analysis of the clinical trial landscape. Mol Ther 2018;26(2):342–53. link1

[15] Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018;378(5):439–48. link1

[16] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377(26):2531–44. link1

[17] Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017;377(26):2545–54. link1

[18] Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168(4):724–40. link1

[19] Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature 2017;545(7655):423–31. link1

[20] Parida SK, Poiret T, Zhenjiang L, Meng Q, Heyckendorf J, Lange C, et al. T-Cell therapy: options for infectious diseases. Clin Infect Dis 2015;61(Suppl 3): S217–24. link1

[21] Drews J. Drug discovery: a historical perspective. Science 2000;287 (5460):1960–4. link1

[22] Drews J. Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov 2006;5(8):635–40. link1

[23] Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103(46):17372–7. link1

[24] Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, et al. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia 2017;31(1):186–94. link1

[25] Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J 2015;17 (6):1327–40. link1

[26] Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, et al. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood 2017;130(21):2317–25. link1

[27] Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 2017;4:92–101. link1

[28] Lacey SF, Kalos M. Biomarkers in T-cell therapy clinical trials. Cytotherapy 2013;15(6):632–40. link1

[29] Novosiadly R, Kalos M. High-content molecular profiling of T-cell therapy in oncology. Mol Ther Oncolytics 2016;3:16009. link1

[30] Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol 2011;162(6):1239–49. link1

[31] Schenone M, Dancˇík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 2013;9(4):232–40. link1

[32] Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today 2012;17(Suppl):S24–30. link1

[33] Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med 2017;9(383):eaag1166. link1

[34] Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin 2010;31(9):1198–207. link1

[35] Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123(17):2625–35. link1

[36] Nicholson IC, Lenton KA, Little DJ, Decorso T, Lee FT, Scott AM, et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997;34(16–17):1157–65. link1

[37] Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009;17(8):1453–64. link1

[38] Cooper GM. The cell: a molecular approach. 2nd ed. Sunderland: Sinauer Associates, Inc.; 2000. link1

[39] Steentoft C, Migliorini D, King TR, Mandel U, June CH, Posey AD Jr. Glycandirected CAR-T cells. Glycobiology 2018;28(9):656–69. link1

[40] Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, et al. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget 2015;6(28):24884–94. link1

[41] Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, et al. A TCR-based chimeric antigen receptor. Sci Rep 2017;7(1):10713. link1

[42] Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells. Front Immunol 2013;4:371. link1

[43] Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348(6230):69–74. link1

[44] Ruella M, Levine BL. Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. Ann Transl Med 2016;4(1):13. link1

[45] O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017;9(399):eaaa0984. link1

[46] Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003;9 (3):279–86. link1

[47] Feng K, Liu Y, Guo Y, Qiu J, Wu Z, Dai H, et al. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers. Protein Cell 2018;9(10):838–47. link1

[48] Gjerstorff MF, Andersen MH, Ditzel HJ. Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 2015;6(18):15772–87. link1

[49] Schultz-Thater E, Noppen C, Gudat F, Dürmüller U, Zajac P, Kocher T, et al. NYESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 2000;83(2):204–8. link1

[50] Draper LM, Kwong ML, Gros A, Stevanovic S, Tran E, Kerkar S, et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin Cancer Res 2015;21(19):4431–9. link1

[51] Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988;71(1):13–29. link1

[52] Zhou LJ, Ord DC, Hughes AL, Tedder TF. Structure and domain organization of the CD19 antigen of human, mouse, and guinea pig B lymphocytes. Conservation of the extensive cytoplasmic domain. J Immunol 1991;147 (4):1424–32. link1

[53] Barrington RA, Schneider TJ, Pitcher LA, Mempel TR, Ma M, Barteneva NS, et al. Uncoupling CD21 and CD19 of the B-cell coreceptor. Proc Natl Acad Sci USA 2009;106(34):14490–5. link1

[54] Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005;5(2):136–48. link1

[55] Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 1987;138(9):2793–9. link1

[56] Castellarin M, Watanabe K, June CH, Kloss CC, Posey Jr AD. Driving cars to the clinic for solid tumors. Gene Ther 2018;25(3):165–75. link1

[57] Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10(5):537–43. link1

[58] Sioud M. Main approaches to target discovery and validation. Methods Mol Biol 2007;360:1–12. link1

[59] Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, et al. 4–1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010;21(1):75–86. link1

[60] Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009;106(9):3360–5. link1

[61] Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med 2015;7 (275):275ra22. link1

[62] Guedan S, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR. Enhancing CAR T cell persistence through ICOS and 4–1BB costimulation. JCI Insight 2018;3 (1):96976. link1

[63] Nadler LM, Anderson KC, Marti G, Bates M, Park E, Daley JF, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983;131(1):244–50. link1

[64] Zola H, Macardle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991;69(6):411–22. link1

[65] Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018;24(10):1499–503. link1

[66] Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med 2017;9(9):1183–97. link1

[67] Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19× CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95(6):2098–103. link1

[68] Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+ :CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126(6):2123–38. link1

[69] Alabanza L, Pegues M, Geldres C, Shi V, Wiltzius JJW, Sievers SA, et al. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther 2017;25 (11):2452–65. link1

[70] Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest 2015;125 (9):3392–400. link1

[71] Wehling M, editor. Principles of translational science in medicine: from bench to bedside. Cambridge: Academic Press; 2015. link1

[72] Choi DW. Exploratory clinical testing of neuroscience drugs. Nat Neurosci 2002;5(Suppl):1023–5. link1

[73] Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer 2016;4:42. link1

[74] Food and Drug Administration. Expanded access to investigational drugs for treatment use—questions and answers: guidance for industry. Silver Spring: Food and Drug Administration; 2017. link1

[75] Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509–18. link1

[76] Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7 (303):303ra139. link1

[77] Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6(6):664–79. link1

[78] Aktas E, Kucuksezer UC, Bilgic S, Erten G, Deniz G. Relationship between CD107a expression and cytotoxic activity. Cell Immunol 2009;254 (2):149–54. link1

[79] Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 2016;8(355):355ra116. link1

[80] DeFrancesco L. CAR-T’s forge ahead, despite Juno deaths. Nat Biotechnol 2017;35(1):6–7. link1

[81] Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 2017;7 (12):1404–19. link1

[82] Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci USA 2011;108(6):2444–9. link1

[83] Tran E, Robbins PF, Rosenberg SA. ‘‘Final common pathway” of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 2017;18(3):255–62. link1

[84] Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, et al. An efficient single-cell RNA-seq approach to identify neoantigen-specific T cell receptors. Mol Ther 2018;26(2):379–89. link1

[85] Wang C, Gu Y, Zhang K, Xie K, Zhu M, Dai N, et al. Systematic identification of genes with a cancer-testis expression pattern in 19 cancer types. Nat Commun 2016;7:10499. link1

[86] Sugiyama A, Umetsu M, Nakazawa H, Niide T, Onodera T, Hosokawa K, et al. A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity. Sci Rep 2017;7(1):2862. link1

[87] Janzen WP. Screening technologies for small molecule discovery: the state of the art. Chem Biol 2014;21(9):1162–70. link1

[88] Terrett NK, Gardner M, Gordon DW, Kobylecki RJ, Steele J. Drug discovery by combinatorial chemistry—the development of a novel method for the rapid synthesis of single compounds. Chem-Eur J 1997;3(12):1917–20. link1

[89] Lerner RA. Combinatorial antibody libraries: new advances, new immunological insights. Nat Rev Immunol 2016;16(8):498–508. link1

[90] Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, et al. Fully human CD19-specific chimeric antigen receptors for T-cell therapy. Leukemia 2017;31(10):2191–9. link1

[91] Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2016;2016(1):567–72. link1

[92] Nassar AF, Ogura H, Wisnewski AV. Impact of recent innovations in the use of mass cytometry in support of drug development. Drug Discov Today 2015;20 (10):1169–75. link1

[93] Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, Swerdlow H, et al. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods 2017;14(9):865–8. link1

[94] Peterson VM, Zhang KX, Kumar N, Wong J, Li L, Wilson DC, et al. Multiplexed quantification of proteins and transcripts in single cells. Nat Biotechnol 2017;35(10):936–9. link1

[95] Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018;24 (5):563–71. link1

[96] Hensley P. SOMAmers and SOMAscan—a protein biomarker discovery platform for rapid analysis of sample collections from bench top to the clinic. J Biomol Tech 2013;24(Suppl):S5. link1

[97] Wilson JJ, Burgess R, Mao YQ, Luo S, Tang H, Jones VS, et al. Antibody arrays in biomarker discovery. Adv Clin Chem 2015;69:255–324. link1

[98] Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, Harris J, et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. Clin Transl Sci 2017;10 (2):84–92. link1

[99] Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, et al. Genome-wide association study of event-free survival in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 2015;33 (33):3930–7. link1

[100] Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS One 2017;12(7):e0179726. link1

[101] Jørgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert Rev Mol Diagn 2016;16(2):131–3. link1

[102] Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology 2008;82(3):171–9. link1

Related Research